there is

a third genesis between patient to patient, but also within the tumor itself, they may also behave differently.

So meaning that even in the liver, for example, we may have different tumors in the liver and it's possible that one of them is kind of like misbehaving.

And then for which maybe some of the therapies that we implemented may not address that misbehaving tumor.

Even within the neuroendocrine tumor, it could be, for example, well differentiated, but maybe there is one of them or one clone, we call him, that may misbehave and may behave differently than the other ones.

And that's something that we need to recognize because in those situations, you know, sometimes we recommend something different just to address that tumor, whether it's ablation or embolization, or there may be other therapies that can be added to the current systemic therapy that a patient is getting.

Some of these tumors may accumulate mutations over time.

Some others, you know, we call it, you know, kind of like epigenetic changes.